108 related articles for article (PubMed ID: 16884365)
1. Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma.
Staflin K; Järnum S; Hua J; Honeth G; Kannisto P; Lindvall M
Int J Gynecol Cancer; 2006; 16(4):1557-64. PubMed ID: 16884365
[TBL] [Abstract][Full Text] [Related]
2. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.
Waltmire CN; Alberts DS; Dorr RT
Anticancer Drugs; 2001 Aug; 12(7):595-602. PubMed ID: 11487716
[TBL] [Abstract][Full Text] [Related]
3. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
4. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
Shnyder SD; Cooper PA; Pettit GR; Lippert JW; Bibby MC
Anticancer Res; 2003; 23(2B):1619-23. PubMed ID: 12820431
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
Yeung SC; She M; Yang H; Pan J; Sun L; Chaplin D
J Clin Endocrinol Metab; 2007 Aug; 92(8):2902-9. PubMed ID: 17550961
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
Shah DK; Veith J; Bernacki RJ; Balthasar JP
Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
[TBL] [Abstract][Full Text] [Related]
8. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664
[TBL] [Abstract][Full Text] [Related]
9. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
10. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Giaccone G; Huizing M; ten Bokkel Huinink W; Koolen M; Postmus P; van Kralingen K; van Zandwijk N; Vermorken J; Beijnen J; Dalesio O
Semin Oncol; 1994 Oct; 21(5 Suppl 8):34-8. PubMed ID: 7939761
[TBL] [Abstract][Full Text] [Related]
12. A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective.
Todo Y; Minobe S; Sasaki M; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Apr; 97(1):223-7. PubMed ID: 15790463
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
14. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Press JZ; Kenyon JA; Xue H; Miller MA; De Luca A; Miller DM; Huntsman DG; Gilks CB; McAlpine JN; Wang YZ
Gynecol Oncol; 2008 Aug; 110(2):256-64. PubMed ID: 18547621
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
20. The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts.
Tourell MC; Shokoohmand A; Landgraf M; Holzapfel NP; Poh PS; Loessner D; Momot KI
Sci Rep; 2017 Feb; 7():42905. PubMed ID: 28220831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
